AZN: H1 2026 revenue up 6% at CER, driven by oncology and rare disease growth, with robust pipeline progressQuartr·9 hours agoAZN+1.18%AZN
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earningsbenzinga_article·1 hour agoAZN+1.18%SPY-0.24%
AstraZeneca Sees 2030 Goal on Track as Cancer Drugs Drive Growth — UpdateMorningStar·4 hours agoAZN+1.18%AZN
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers | AZN Stock NewsStockTitan·12 hours agoAZN+1.18%AZN
CSPC Sees Profit Surge on AstraZeneca Deal and Solid Drug SalesTip Ranks·6 hours ago01093-2.92%AZN+1.18%
AstraZeneca Q2 Pre-tax Profit Drops, Revenues Rise; Confirms FY26 Outlookrttnews·9 hours agoAZN+1.18%AZN
AstraZeneca Q2 profit beats estimates as cancer drug sales drive growthbusinessinsider·7 hours agoAZN+1.18%AZN
